Veopoz Injection, Solution
Product Images NDC 61755-014

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Veopoz (NDC 61755-014). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Regeneron Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Pozelimab 01)

A line graph showing albumin levels (g/dL) over weeks, ranging from -48 to 72 weeks. Multiple lines represent individual or grouped data trends, with a marked increase in albumin levels around week 0, reaching above 3.5 g/dL and stabilizing thereafter. The x-axis is labeled 'Weeks' and the y-axis is labeled 'Albumin (g/dL)'.*

FDA Label Image

Principal Display Panel (2 mL Vial Carton)

Packaging label for Veopoz (pozelimab-bbfg) injection, 400 mg/2 mL (200 mg/mL) solution for intravenous infusion after dilution or subcutaneous use. The label indicates a single-dose vial with instructions to discard unused portions, manufactured by Regeneron Pharmaceuticals, Inc. It includes the NDC 61755-014-01 and states it is Rx only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.